Case studies in anticoagulation management

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 1, 2008, Pages 78-84

  Leong, Wendy A ^a  

^a Burnaby Research   (Canada)

Author keywords

Anticoagulation; Bridging; Low molecular weight heparin; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMLODIPINE; ARGATROBAN; ATORVASTATIN; ENALAPRIL; ENOXAPARIN; FOLIC ACID; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROMORPHONE; LINEZOLID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARACETAMOL; PREDNISONE; SUMATRIPTAN; TERAZOSIN; TINZAPARIN; VITAMIN K GROUP; WARFARIN;

ADULT; ALOPECIA; ANAMNESIS; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BEDTIME DOSAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; HEADACHE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MALE; MITRAL VALVE REPLACEMENT; OSTEOPOROSIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPONTANEOUS ABORTION; TEMPORAL ARTERITIS; THROMBOCYTE COUNT; TOOTH EXTRACTION; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ADULT; AGED; ALOPECIA; ANTICOAGULANTS; DRUG MONITORING; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; THROMBOCYTOPENIA; WARFARIN;

EID: 38049152996     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0109-6     Document Type: Conference Paper

References (61)

1. Leong WA (2004) Anticoagulation opportunities for community pharmacists. Pharm Practice 20(11):CE1-8
2. Ansell J, Hollowell J, Pengo V et al (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23(2):83-91
3. Ansell JE, Oertel LB and Wittkowsky AK (eds) (2003) Managing Oral Anticoagulation: Clinical & Operational Guidelines, 2nd edn. Aspen Publishers, New York, NY
4. Ansell JE, the Anticoagulation Guidelines Task Force (1997) Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 31:604-615
5. Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S-233S
6. Surgical management of the primary care dental patient on warfarin Revised March (2006) North West Medicines Information Centre, Liverpool, England. (http://www.dundee.ac.uk/tuith/Static/info/warfarin.pdf). Accessed on April 2007
7. Salem DN, Stein PD, Al-Ahmad A et al (2004) Antithrombotic therapy in valvular heart disease - native and prosthetic: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:457S-482S
8. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S-203S
9. Douketis JD, Woods K, Crowther MA (2005) Anticoagulation management of patients undergoing elective surgery who require temporary interruption of warfarin therapy. 2nd edn. McMaster University Dept. of Medicine and St. Joseph's Healthcare, Hamilton, Canada
10. Mannucci C, Douketis JD (2006) The management of patients who require temporary reversal of vitamin K antagonists for surgery: A practical guide for clinicians. Intern Emerg Med 1(2):94-95
11. Spyropoulos AC, Turpie AG, Dunn AS et al (2006) Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: The REGIMEN registry. J Thromb Haemost 4(6):1246-1252
12. Dunn A (2006) Perioperative management of oral anticoagulation: When and how to bridge. J Thromb Thrombolysis 21(1):85-89
13. Meurin P, Tabet JY, Weber H et al (2006) Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 113(4):564-569
14. O'Donnell MJ, Kearon C, Johnson J et al (2007) Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146(3):184-187
15. Deerhake JP, Merz JC, Cooper JV et al (2007) The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis 23(2):107-13
16. Douketis JD, Woods K, Foster GA et al (2005) Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 94(3):528-531
17. Leong WA (1998) Outpatient deep vein thrombosis treatment models. Pharmacotherapy 18(6 Pt 3):170S-174S
18. Hulse ML (1996) Warfarin resistance: Diagnosis and therapeutic alternatives. Pharmacotherapy 16(6):1009-1017
19. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537-541
20. Yasar AS, Balbay Y, Maden O et al (2007) Early mechanical mitral valve thrombosis in a patient with warfarin resistance. J Heart Valve Dis 16(2):200-202
21. Holt RJ, Freytes CO (1983) Familial warfarin resistance. Drug Intell Clin Pharm 17(4):281-283
22. Alving BM, Strickler MP, Knight RD et al (1985) Hereditary warfarin resistance. investigation of a rare phenomenon. Arch Intern Med 145(3):499-501
23. Dager WE, Dougherty JA, Nguyen PH et al (2007) Heparin-induced thrombocytopenia: Treatment options and special considerations. Pharmacotherapy 27(4):564-587
24. Taylor LM, Smith KM (2005) The paradox of heparin-induced thrombocytopenia: Future anticoagulation. Orthopedics 28(7):651-654
25. Attassi K, Hershberger E, Alam R et al (2002) Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34(5):695-698
26. Waldrep TW, Skiest DJ (2002) Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 22(1):109-112
27. Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 46(8):2723-2726
28. Greinacher A, Warkentin TE (2006) Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thromb Res 118(2):165-176
29. Gruel Y, Pouplard C, Nguyen P et al (2003) Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Hematol 121(5):786-792
30. Warkentin TE (2002) Heparin-induced thrombocytopenia: Part 1. J Crit Illness 17(5):172-178
31. Spinler SA, Dager WE (2003) Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 60:S5-S11
32. Spinler SA (2003) Managing heparin-induced thrombocytopenia: Preventing life- and limb-threatening thrombosis. Am J Health Syst Pharm 60:S2-S4
33. Girolami B, Girolami A (2006) Heparin-induced thrombocytopenia: A review. Semin Thromb Hemost 32(8):803-809
34. Keeling D, Davidson S, Watson H (2006) The management of heparin-induced thrombocytopenia. Br J Haematol 133(3):259-269
35. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):311S-337S
36. Andreescu AC, Cushman M (2000) Case studies in heparin-induced thrombocytopenia. J Thromb Thrombolysis 10(Suppl):71-76
37. Nagao T, Ibayashi S, Fujii K et al (1995) Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 346:1104-1105
38. Akihama T, Nakamoto Y, Shindo T et al (1983) Protective effects of Coenzyme Q10 on the adverse reactions of anthracycline antibiotics. Gan To Kagaku Ryoho (Cancer & Chemotherapy) 10(10):2125-2129, [Article in Japanese]
39. Frishman WH, Brosnan BD, Grossman M et al (2002) Adverse dermatologic effects of cardiovascular drug therapy: Part II. Cardiol in Rev 10(5):285-300
40. Ahmad S (1991) Enalapril and reversible alopecia. Arch Intern Med 151(2):404
41. Motel PJ (1990) Captopril and alopecia: A case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol 23(1):124-125
42. Thiedke C (2003) Alopecia in women. Am Fam Physician 67:1007-1014, 1017-1018
43. Umlas J, Harken DE (1988) Warfarin-induced alopecia. Cutis 42(1):63-64
44. Kaur M and Kern M (2002) Warfarin sodium induced alopecia. Pharmascript 25(7)
45. Anon (1995) A close shave... warfarin induced alopecia. ADRB 173:655-658
46. Wang YY, Po HL (2006) Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 31(5):513-517
47. Sarris E, Tsele E, Bagiatoudi G et al (2003) Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis 41(5):E15
48. Qureshi GD, Reinders TP, Swint JJ et al (1981) Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 141(4):507-519
49. Reese AM, Farnett LE, Lyons RM et al (2005) Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 25(12):1746-1751
50. Hartig C, Lang M, Weibert R (2007) Low-dose daily vitamin K supplement in patients anticoagulated with warfarin. Abstract presented at the anticoagulation forum 9th National Conference in Chicago, Illinois
51. Ford SK, Misita CP, Shilliday BB et al (2007) Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis 24(1):23-27, Epub 2007 Feb 24
52. Ford S, Moll S (2007) Supplemental vitamin K in patients on warfarin with unstable INRs. J Thromb Thrombolysis 24(1):23-27
53. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: A systematic review. JAMA 295(9):1050-1057
54. Ortel TL (2006) The antiphospholipid syndrome: What are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 21(1):79-83
55. Crowther MA, Wisloff F (2005) Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 115(1-2):3-8
56. Erkan D, Lockshin MD (2004) How much warfarin is enough in APS related thrombosis? Thromb Res 114(5-6):435-442
57. Erkan D, Lockshin MD (2006) Antiphospholipid syndrome. Curr Opin Rheumatol 18(3):242-248
58. Sucker C, Wenzel F, Zotz RB et al (2006) Monitoring oral anticoagulation may require determination of single coagulation factor activities in patients with antiphospholipid syndrome. J Rheumatol 33(9):1881-1882
59. Moll S, Oertel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127(3):177-185
60. Wittkowsky AK, Downing J, Blackburn J et al (2006) Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 96(2):137-141
61. Sconce E, Avery P, Wynne H et al (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419-2433